#Denmark #Copenhagen #CathVision #electrophysiology #PFAnalyzer

CathVision Breaks New Ground in Electrophysiology with PFAnalyzer

CathVision, a pioneering force in the realm of electrophysiology, has recently revealed groundbreaking advancements in Pulsed Field Ablation (PFA) through its state-of-the-art PFAnalyzer™ software module. This announcement marks a significant leap forward in electrophysiology, particularly in lesion assessment and electrogram analysis.

In a clinical study conducted in collaboration with the University Hospital of Split, Croatia, and Mount Sinai in New York, CathVision has showcased its commitment to improving medical outcomes through innovative technologies. The study, featured in a research letter in the renowned journal Heart Rhythm, confirmed the existence of a clinically viable low-amplitude unipolar voltage threshold around the ~0.1 mV range. This threshold effectively differentiates between electrically silent tissue and residual electrical activity following PFA treatment.

Traditionally, these low-amplitude unipolar signals were either ignored or deemed too complex to interpret. However, using CathVision’s ECGenius™ EP Recording System, these signals can now be measured and visualized with the PFAnalyzer™, bringing a new level of clarity and detail to the procedure. The findings underline that clinical efficacy can be achieved with these previously overlooked signals, emphasizing their significance in real-time ablation therapy.

Key Findings from the Study

1. Separation of Signals: The data confirms a clear distinction between areas of electrically silent tissue and those with residual local activity, even at voltage levels previously considered unusable for clinical application.
2. Feasibility of Unipolar Electrograms: The study has shown the practicality of using unipolar electrograms for objective lesion assessment in PFA procedures, offering actionable insights to healthcare practitioners during the process.
3. Real-Time Feedback: This innovative approach provides electrophysiological feedback that can inform decision-making on the spot, a significant improvement over relying on retrospective evaluation.

In an era where PFA adoption is rapidly increasing, the need for direct electrophysiological feedback has become more critical than ever. The lack of such feedback has often led to dependence on surrogate endpoints, which can compromise the efficacy of ablation procedures. With electrophysiological factors such as ablation durability and tissue reconnection being pivotal contributors to patient recurrence, the capability for real-time analysis with the PFAnalyzer offers promise in enhancing procedural outcomes.

Dr. Ante Anić, a prominent figure at the University Hospital of Split, emphasizes that the insights derived from this work highlight the clinical relevance of previously dismissed signals in PFA. He states, “What this work shows is that clinically meaningful information is still present in PFA - down to voltage levels we previously could not use.” The PFAnalyzer is paving the way for actionable signal analysis during electrophysiology procedures, underscoring the potential for better patient outcomes.

Upcoming Engagements at AF Symposium

CathVision's remarkable progress in PFA will be featured in various presentations at the upcoming AF Symposium:

• - Oral Spotlight Presentation: Scheduled for February 5th at 8:45 AM, Dr. Ante Anić will present key findings on “PFAnalyzer Electrogram-guided Pulsed Field Ablation.”
• - Poster Presentations include topics like “A Clinically Meaningful Threshold for Residual Local Potentials” and “Evaluation of Electrode Contact Through Signal Amplitude,” showcasing the comprehensive research efforts behind these innovations.

While the PFAnalyzer™ is currently not approved for market sale, it embodies CathVision's mission to advance the field of electrophysiology with superior signal acquisition and actionable analytics. By harnessing the full potential of electrograms, CathVision seeks to transform the landscape of cardiac ablation, particularly as it pertains to the emerging techniques like pulsed field ablation. CathVision continues to stand at the forefront of medical technology, dedicated to enhancing clinical outcomes and optimizing patient care in the ever-evolving field of cardiology.